{"id":"W2165050668","doi":"10.1016/s1473-3099(11)70374-7","title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Infectious Diseases","topic":"Clostridium difficile and Clostridium perfringens research","field":"Medicine","cited_by":752,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec","funders":"","keywords":"Fidaxomicin; Medicine; Clostridium difficile; Vancomycin; Internal medicine; Clinical endpoint; Population; Diarrhea; Randomized controlled trial; Clinical trial; Surgery; Pediatrics; Antibiotics; Staphylococcus aureus; Microbiology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0391967485357323,"score_gpt":0.313839803536039,"score_spread":0.2746430550003067,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}